Iambic Therapeutics files for proposed IPO

Iambic Therapeutics has officially filed for a US IPO to secure funding for the development of cancer drugs. The company is backed by Nvidia and QIA, reflecting a broader biotech boom. This move highlights the transformative role of AI in biotech, with the potential to reshape drug discovery and investment landscapes. The filing comes as the industry sees increased momentum in integrating artificial intelligence to accelerate the creation of new pharmaceutical treatments for various diseases.